| Bryan K Matanky, MD | |
|
1760 E Florence Blvd, Suite 120, Casa Grande, AZ 85222-4764 | |
| (520) 426-1000 | |
| (520) 426-1395 |
| Full Name | Bryan K Matanky |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 37 Years |
| Location | 1760 E Florence Blvd, Casa Grande, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205945482 | NPI | - | NPPES |
| 200018286 | Other | AZ | RR MEDICARE |
| F66298 | Other | AZ | MERCY HEALTH PLANS |
| 0046722 | Other | AZ | DEPT. LABOR |
| 1Z1375 | Other | AZ | HEALTHNET |
| 86-0754243 | Other | AZ | IRS TAX ID |
| 15781901 | Medicaid | AZ | |
| AZ0351140 | Other | AZ | BC/BS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 22110 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Casa Grande Medical Center | Casa grande, AZ | Hospital |
| Arizona Orthopedic And Surgical Specialty Hospital | Chandler, AZ | Hospital |
| Huhu Kam Memorial Hospital | Sacaton, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Orthopaedics And Sports Medicine, Pc | 4385558030 | 2 |
News Archive
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.
Orexigen Therapeutics, Inc., today announced that Contrave (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.
A new study of the U.K. and South Africa variants of SARS-CoV-2 predicts that current vaccines and certain monoclonal antibodies may be less effective at neutralizing these variants and that the new variants raise the specter that reinfections could be more likely.
› Verified 2 days ago
| Entity Name | Advanced Orthopaedics And Sports Medicine, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417066788 PECOS PAC ID: 4385558030 Enrollment ID: O20031117000622 |
News Archive
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.
Orexigen Therapeutics, Inc., today announced that Contrave (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.
A new study of the U.K. and South Africa variants of SARS-CoV-2 predicts that current vaccines and certain monoclonal antibodies may be less effective at neutralizing these variants and that the new variants raise the specter that reinfections could be more likely.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bryan K Matanky, MD 1760 E Florence Blvd, Suite 120, Casa Grande, AZ 85222-4764 Ph: (520) 426-1000 | Bryan K Matanky, MD 1760 E Florence Blvd, Suite 120, Casa Grande, AZ 85222-4764 Ph: (520) 426-1000 |
News Archive
Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.
The US Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate), Boehringer Ingelheim's novel, oral direct thrombin inhibitor for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.S. in more than 50 years.
Orexigen Therapeutics, Inc., today announced that Contrave (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.
A new study of the U.K. and South Africa variants of SARS-CoV-2 predicts that current vaccines and certain monoclonal antibodies may be less effective at neutralizing these variants and that the new variants raise the specter that reinfections could be more likely.
› Verified 2 days ago
Dr. Thomas L Erickson, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1780 E Florence Blvd, Suite 106, Casa Grande, AZ 85222 Phone: 520-836-8988 Fax: 520-836-7930 |